TIDMAGL
Angle PLC
14 June 2022
For immediate release 14 June 2022
ANGLE plc ("the Company")
PARSORTIX STUDY SHOWS POTENTIAL ROLE OF INVASIVE CELLULAR
PROTRUSIONS IN THE FORMATION OF PROSTATE CANCER CTCs
Prostate cancer cells may use invasive cellular protrusions to
aid entry into the blood stream, a potential target in the
metastatic process for novel therapy development
Parsortix system isolates CTCs in 94% of prostate cancer
patients, showing some association with matrix degradation and
invasive cellular protrusion formation
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that researchers at King's College
London, UK, have published data investigating the role of invasive
cellular protrusion, known as invadopodia, activity in prostate
cancer, and a potential role in the formation of circulating tumour
cells (CTCs). This novel finding has the potential to provide a new
target, within the metastatic process, for the development of novel
therapeutics in the prostate cancer setting.
Invasive cellular protrusions are thought to be involved in
degradation of the extracellular matrix (ECM), driving tumour
invasion and metastasis. Formation of invasive cellular protrusions
has been seen in many metastatic cancer cell lines, but there has
previously been little evidence in prostate cancer cell lines.
Firstly, the authors of this study have identified prostate cancer
cell lines that form spontaneous invasive cellular protrusions in
vitro, and show metastatic behaviour in vivo, proving to be a valid
model for future studies.
In addition, the researchers used ANGLE's marker-independent
Parsortix (R) system to isolate CTCs from prostate cancer patients
with a Gleason score >=7 (medium to high grade cancer). CTCs
were identified in 16 out of 17 patients, with 8 patients having 10
or more CTCs. Overall, 75% of patients showed evidence of ECM
degradation near the CTCs, and 40% of patients had invasive
cellular protrusion presence aligning with ECM degradation. The
authors speculate that prostate cancer cells detaching from the
primary tumour may use the invasive cellular protrusions to aid
entry into the blood stream. There is the potential for novel
therapy development targeting this step in the metastatic
process.
The Parsortix system's ability to effectively isolate CTCs from
the blood of prostate cancer patients may allow novel therapeutic
development targeting the mechanisms of invadopodia and reducing
metastatic spread of the cancer.
Prostate cancer is the most common cancer in men. The American
Cancer Society estimates that there will be 268,490 new cases in
the US in 2022. For localised disease the 5-year relative survival
is 100%, this drops to only 30.6% when the cancer has metastasised,
suggesting a need for better targeted treatment that could prevent
the early stages of metastasis, improving survival for prostate
cancer patients.
Professor Claire Wells, School of Cancer and Pharmaceutical
Sciences, King's College London, commented:
"We have found that prostate cancer CTCs form invadopodia
structures and are intrinsically capable of degrading the matrix;
our novel finding paves the way for a new series of studies. Our
study supports further exploration of invadopodia activity in the
prostate cancer setting with the potential to develop novel
therapeutics."
ANGLE Founder and Chief Executive, Andrew Newland, added:
"We are pleased to report on the use of the Parsortix system for
the unbiased isolation of CTCs in prostate cancer, revealing a
potentially novel understanding of prostate cancer CTC formation.
This research suggests a potential for the development of novel
therapeutics targeting the early stages of prostate cancer
metastasis, which is important for improving patient survival."
The research has been published as a peer-reviewed publication
in the Journal BMC Cancer and is available online at
https://angleplc.com/library/publications/ .
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Max Jones, Thomas Bective +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology known as the Parsortix(R) system and a downstream
analysis system for cost effective, highly multiplexed analysis of
nucleic acids and proteins.
ANGLE's Parsortix(R) system is FDA cleared for its intended use
in metastatic breast cancer and is currently the first and only FDA
cleared medical device to harvest intact circulating cancer cells
from blood.
Intended use
The Parsortix(R) PC1 system is an in vitro diagnostic device
intended to enrich circulating tumor cells (CTCs) from peripheral
blood collected in K(2) EDTA tubes from patients diagnosed with
metastatic breast cancer. The system employs a microfluidic chamber
(a Parsortix cell separation cassette) to capture cells of a
certain size and deformability from the population of cells present
in blood. The cells retained in the cassette are harvested by the
Parsortix PC1 system for use in subsequent downstream assays. The
end user is responsible for the validation of any downstream assay.
The standalone device, as indicated, does not identify, enumerate
or characterize CTCs and cannot be used to make any
diagnostic/prognostic claims for CTCs, including monitoring
indications or as an aid in any disease management and/or treatment
decisions.
The Parsortix system enables a liquid biopsy (a simple blood
test) to be used to provide the circulating metastatic breast
cancer cells to the user in a format suitable for multiple types of
downstream analyses. The system is based on a microfluidic device
that captures cells based on a combination of their size and
compressibility. The system is epitope independent and can capture
all phenotypes of CTCs (epithelial, mesenchymal and EMTing CTCs) as
well as CTC clusters in a viable form (alive). CTCs harvested from
the system enable a complete picture of a cancer to be seen; as
being an intact cell they allow DNA, RNA and protein analysis as
well as cytological and morphological examination and may provide
comparable analysis to a tissue biopsy in metastatic breast cancer.
Because CTC analysis is a non-invasive process, unlike tissue
biopsy, it can be repeated as often as needed. This is important
because cancer develops and changes over time and there is a clear
medical need for up-to-date information on the status of a
patient's tumor. In addition, the live CTCs harvested by the
Parsortix system can be cultured, which offers the potential for
testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
In the United States, the Parsortix(R) PC1 system has received a
Class II Classification from FDA for use with metastatic breast
cancer patients. FDA clearance is seen as the global gold standard.
ANGLE's Parsortix system is the first ever FDA cleared system for
harvesting CTCs for subsequent analysis. ANGLE has applied the IVD
CE Mark to the same system for the same intended use in Europe.
ANGLE has also completed two separate 200 subject clinical
studies under a program designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has
undergone further refinement and optimisation and a 200 patient
clinical verification study has now completed enrolment.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) platform and is
based on a patented flow through array technology. It provides for
low cost, highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry approach (the HyCEAD method) allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. The HyCEAD system is extremely sensitive and is ideal for
measuring gene expression and other markers directly from Parsortix
harvests and was used in the ovarian cancer pelvic mass triage test
to achieve best in class accuracy (AUC-ROC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
61 peer-reviewed publications and numerous publicly available
posters from 31 independent cancer centres, available on our
website.
ANGLE has established clinical services laboratories in the UK
and the United States to accelerate commercialisation of the
Parsortix system and act as demonstrators to support product
development. The laboratories offer services globally to
pharmaceutical and biotech customers for use of Parsortix in cancer
drug trials and, once the laboratories are accredited and tests
validated, will provide Laboratory Developed Tests (LDTs) for
patient management.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADBGDLXDBDGDX
(END) Dow Jones Newswires
June 14, 2022 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024